Literature DB >> 19351735

Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2.

Assel Biyasheva1, Richard S Legro, Andrea Dunaif, Margrit Urbanek.   

Abstract

CONTEXT AND
OBJECTIVE: Of the recently identified type 2 diabetes mellitus (T2D) susceptibility loci, transcription factor 7-like 2 (TCF7L2) confers the greatest relative risk for T2D and significantly predicts conversion to T2D in persons with impaired glucose tolerance. TCF7L2 is, therefore, also a strong candidate gene for polycystic ovary syndrome (PCOS), a common endocrine disorder characterized by androgen excess and menstrual irregularities and associated with insulin resistance and a 7-fold increased risk for T2D. RESEARCH DESIGN AND METHODS: We tested for association between 58 single nucleotide polymorphisms mapping to TCF7L2 and PCOS in 624 index (PCOS) cases and 553 control women of European ancestry. Furthermore, in the women with PCOS, we tested for association with seven reproductive and metabolic quantitative traits.
RESULTS: Although we did not detect evidence for association between the previously described TCF7L2 T2D locus, the proinsulin:insulin molar ratio, a marker of pancreatic beta-cell dysfunction, was strongly associated with this locus (P = 2.1 x 10(-4)). We also observed evidence for association between PCOS and two single nucleotide polymorphisms, rs11196236 (P = 9.0 x 10(-4)) and rs11196229 (P = 0.0027) mapping more than 100 kb centromeric to the previously published T2D susceptibility loci.
CONCLUSIONS: We have observed evidence of association with two independent TCF7L2 loci in a PCOS cohort: 1) association between the proinsulin:insulin molar ratio and the T2D locus; and 2) association with reproductive PCOS phenotype and a novel locus. This study suggests that variation in different regions of a susceptibility gene contributes to distinct phenotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351735      PMCID: PMC2708958          DOI: 10.1210/jc.2008-1664

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  Insulin resistance does not change the ratio of proinsulin to insulin in normal volunteers.

Authors:  P W Wang; F Abbasi; M Carantoni; Y D Chen; S Azhar; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

3.  Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  M E Røder; D Porte; R S Schwartz; S E Kahn
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.

Authors:  Richard S Legro; Rhonda Bentley-Lewis; Deborah Driscoll; Steve C Wang; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

Review 5.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

6.  Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.

Authors:  Bülent O Yildiz; Hakan Yarali; Havva Oguz; Miyase Bayraktar
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

7.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

Authors:  R S Legro; D Driscoll; J F Strauss; J Fox; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

Review 8.  The phenotypic consequences of CFTR mutations.

Authors:  Rebecca K Rowntree; Ann Harris
Journal:  Ann Hum Genet       Date:  2003-09       Impact factor: 1.670

9.  Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome.

Authors:  Lema Haddad; Julie C Evans; Neda Gharani; Carole Robertson; Karen Rush; Steven Wiltshire; Timothy M Frayling; Terence J Wilkin; Andrew Demaine; Ann Millward; Andrew T Hattersley; Gerry Conway; Nancy J Cox; Graeme I Bell; Steve Franks; Mark I McCarthy
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

Authors:  R S Legro; A R Kunselman; W C Dodson; A Dunaif
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

View more
  28 in total

1.  Persistent apparent pancreatic β-cell defects in premenarchal PCOS relatives.

Authors:  Laura C Torchen; Naomi R Fogel; Wendy J Brickman; Rodis Paparodis; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

2.  Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes.

Authors:  R Saxena; C K Welt
Journal:  Acta Diabetol       Date:  2012-03-03       Impact factor: 4.280

3.  Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome.

Authors:  Kathryn G Ewens; Michelle R Jones; Wendy Ankener; Douglas R Stewart; Margrit Urbanek; Andrea Dunaif; Richard S Legro; Angela Chua; Ricardo Azziz; Richard S Spielman; Mark O Goodarzi; Jerome F Strauss
Journal:  Fertil Steril       Date:  2011-03-27       Impact factor: 7.329

4.  Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome.

Authors:  Gregorio Chazenbalk; Yen-Hao Chen; Saleh Heneidi; Jung-Min Lee; Marita Pall; Yii-Der Ida Chen; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

5.  Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.

Authors:  Mark O Goodarzi; Michelle R Jones; Xiaohui Li; Angela K Chua; Obed A Garcia; Yii-Der I Chen; Ronald M Krauss; Jerome I Rotter; Wendy Ankener; Richard S Legro; Ricardo Azziz; Jerome F Strauss; Andrea Dunaif; Margrit Urbanek
Journal:  J Med Genet       Date:  2011-12-17       Impact factor: 6.318

Review 6.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 7.  Genetics of polycystic ovary syndrome.

Authors:  Corrine K Welt; Jessica M Duran
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 9.  Genetics of the polycystic ovary syndrome.

Authors:  Gülüm Kosova; Margrit Urbanek
Journal:  Mol Cell Endocrinol       Date:  2012-10-16       Impact factor: 4.102

10.  Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome.

Authors:  Sidika E Karakas; Kyoungmi Kim; Antoni J Duleba
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.